Publicacions en col·laboració amb investigadors/es de Centro Nacional de Investigaciones Cardiovasculares Carlos III (9)

2023

  1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  2. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

2021

  1. Oxygen-sensitivity and pulmonary selectivity of vasodilators as potential drugs for pulmonary hypertension

    Antioxidants, Vol. 10, Núm. 2, pp. 1-14

  2. Restoration of vitamin d levels improves endothelial function and increases task-like k+ currents in pulmonary arterial hypertension associated with vitamin d deficiency

    Biomolecules, Vol. 11, Núm. 6

2020

  1. Na+ controls hypoxic signalling by the mitochondrial respiratory chain

    Nature, Vol. 586, Núm. 7828, pp. 287-291

  2. Uncovered Contribution of Kv7 Channels to Pulmonary Vascular Tone in Pulmonary Arterial Hypertension

    Hypertension, Vol. 76, Núm. 4, pp. 1134-1146

2018

  1. Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. Effects of quercetin in a rat model of hemorrhagic traumatic shock and reperfusion

    Molecules, Vol. 21, Núm. 12

2006

  1. The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells

    Biochemical and Biophysical Research Communications, Vol. 346, Núm. 3, pp. 919-925